Skip to search formSkip to main contentSkip to account menu

ABT-737

Known as: BH3 Mimetic ABT-737 
An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Biphenyl CompoundsNitrophenolsPiperazinesSulfonamides
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Highly Cited
2012
Highly Cited
2012
Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.
Pim serine/threonine kinases contribute to prostate tumorigenesis and therapeutic resistance, yet Pim kinase inhibitors seem to… 
2012
2012
Doubts concerning functional endothelial nitric oxide synthase in human erythrocytes.
To the editor: Nitric oxide (NO) is involved in the modulation of multiple physiologic functions. NO is produced from L-Arg by… 
2011
2011
ABT-737 synergizes with Bortezomib to kill melanoma cells
Summary The BH3 mimetic ABT-737 is a potent inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XL, and Bcl-w. The Bcl-2 family… 
2010
2010
Inhibition of Bcl‐2 and Bcl‐X enhances chemotherapy sensitivity in hepatoblastoma cells
An increased expression of anti‐apoptotic proteins is regularly found in malignant cells, contributing to their clonal expansion… 
2010
2010
New potential anti‐cancer agents synergize with bortezomib and ABT‐737 against prostate cancer
We previously described the identification of a transcriptional inhibitor ARC and FoxM1 inhibitors, thiazole antibiotics… 
2010
2010
The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics
Mast cells and their mediators are implicated in the pathogenesis of many different diseases. One possible therapeutic… 
Highly Cited
2008
Highly Cited
2008
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Deregulated Myc expression drives many human cancers, including Burkitt's lymphoma and a highly aggressive subset of diffuse… 
Highly Cited
2008
Highly Cited
2008
Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737
Purpose: The intrinsic drug resistance of colorectal cancers is related in part to overexpression of prosurvival Bcl-2 family… 
Highly Cited
2007
Highly Cited
2007
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia
Bcr-Abl is the cause of Philadelphia-positive (Ph+) leukemias and also constitutes their principal therapeutic target, as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)